EA201691143A1 - Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии - Google Patents

Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии

Info

Publication number
EA201691143A1
EA201691143A1 EA201691143A EA201691143A EA201691143A1 EA 201691143 A1 EA201691143 A1 EA 201691143A1 EA 201691143 A EA201691143 A EA 201691143A EA 201691143 A EA201691143 A EA 201691143A EA 201691143 A1 EA201691143 A1 EA 201691143A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biomarkers
treatment
methods
malignant tumors
indicator
Prior art date
Application number
EA201691143A
Other languages
English (en)
Inventor
Мэттью Уилльям Бернелл Троттер
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of EA201691143A1 publication Critical patent/EA201691143A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящей заявке, в некоторых вариантах осуществления, предложены биомаркеры для применения в прогнозировании клинической чувствительности гематологических злокачественных опухолей, таких как неходжкинская лимфома, и ответа пациента на лечение иммуномодулирующим средством, таким как 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-дион, который также известен как леналидомид или Ревлимид®. Также в настоящей заявке, в некоторых вариантах осуществления, предложены способы лечения или контроля неходжкинских лимфом, в том числе, без ограничения перечисленным, диффузной В-крупноклеточной лимфомы (ДВККЛ), с применением прогностических факторов.
EA201691143A 2013-12-06 2014-12-05 Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии EA201691143A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913046P 2013-12-06 2013-12-06
PCT/US2014/068767 WO2015085160A2 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies

Publications (1)

Publication Number Publication Date
EA201691143A1 true EA201691143A1 (ru) 2016-11-30

Family

ID=53274284

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691143A EA201691143A1 (ru) 2013-12-06 2014-12-05 Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии

Country Status (12)

Country Link
US (1) US20160312292A1 (ru)
EP (1) EP3077547A4 (ru)
JP (1) JP2017503481A (ru)
KR (1) KR20160090390A (ru)
AU (1) AU2014360316A1 (ru)
BR (1) BR112016012792A2 (ru)
CA (1) CA2932266A1 (ru)
EA (1) EA201691143A1 (ru)
IL (1) IL245936A0 (ru)
MX (1) MX2016007179A (ru)
PH (1) PH12016501023A1 (ru)
WO (1) WO2015085160A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
AU2014360328B2 (en) 2013-12-06 2021-04-01 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
WO2016060557A1 (en) * 2014-10-17 2016-04-21 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Image analysis method supporting illness development prediction for a neoplasm in a human or animal body
EP3304076A4 (en) 2015-06-02 2018-12-19 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
WO2017044793A1 (en) 2015-09-11 2017-03-16 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of cereblon
CA2999179A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
MX2018008421A (es) 2016-01-08 2019-12-09 Celgene Corp Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
US20200270703A1 (en) * 2017-09-29 2020-08-27 Kyushu University, National University Corporation Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients
US20210116454A1 (en) * 2019-10-21 2021-04-22 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085234A2 (en) * 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
US20110223157A1 (en) * 2010-03-12 2011-09-15 Schafer Peter H Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
MX353482B (es) * 2011-04-29 2018-01-16 Celgene Corp Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.

Also Published As

Publication number Publication date
KR20160090390A (ko) 2016-07-29
BR112016012792A2 (pt) 2017-08-08
CA2932266A1 (en) 2015-06-11
MX2016007179A (es) 2016-09-08
IL245936A0 (en) 2016-07-31
AU2014360316A1 (en) 2016-06-16
JP2017503481A (ja) 2017-02-02
PH12016501023A1 (en) 2016-07-04
EP3077547A2 (en) 2016-10-12
EP3077547A4 (en) 2017-11-08
WO2015085160A2 (en) 2015-06-11
US20160312292A1 (en) 2016-10-27
WO2015085160A3 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
EA201691143A1 (ru) Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии
IL260774B (en) Preparations containing 3cd19 x cd bispecific antibodies for the treatment of tumors of lymph node tissue and/or extra-lymph node lymphoma as a result of diffuse large b-cell lymphoma (dlbcl)
WO2016196298A8 (en) Therapeutic and diagnostic methods for cancer
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
MX2021006893A (es) Acidos nucleicos libres de celulas para el analisis del microbioma humano y componentes del mismo.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
MX352436B (es) Atribución de acción de usuario con base en identidad biométrica.
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2017024019A8 (en) Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
JP2017503481A5 (ru)
MX2017006537A (es) Anticuerpos contra metabolitos de serotonina, triptofano y cinurenina, y usos de los mismos.
TR201908660T4 (tr) Düşük dozda naltrekson i̇le kanser hücreleri̇ni̇n teti̇klenmesi̇.
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201401201A1 (ru) Способ
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы